All articles tagged with #jak inhibitors
A new study in JAMA Dermatology confirms that upadacitinib, an arthritis drug, effectively treats severe alopecia areata. In two Phase 3 trials, 55% of patients on the higher dose achieved 80% scalp coverage, with some reaching full regrowth. The treatment showed early efficacy and improved quality of life, though long-term safety data remains limited.
Upadacitinib, a JAK inhibitor originally developed for rheumatoid arthritis, has demonstrated significant efficacy in treating severe alopecia areata. Phase 3 trials published in JAMA Dermatology indicate that 55% of patients on the 30 mg dose achieved 80% scalp coverage within 24 weeks, with up to 23% experiencing complete hair regrowth. The drug is already approved in Europe but remains under FDA review in the United States.
Two international Phase 3 trials demonstrate that upadacitinib, an oral JAK inhibitor originally developed for arthritis, significantly reverses severe alopecia areata. Published in JAMA Dermatology on August 12, 2026, the study found that 55% of patients achieved 80% scalp coverage within 24 weeks, with 20% reaching complete hair restoration. While the drug is already approved in Europe, it remains under FDA review in the US, and researchers caution that long-term safety data is still required.
A phase 3 trial found that upadacitinib, a JAK inhibitor used for rheumatoid arthritis, helped 50-54% of patients with severe alopecia areata achieve 80% scalp hair coverage within 24 weeks. The drug is already approved in Europe but awaits FDA review in the US.
A once-daily pill called upadacitinib has shown promise in restoring skin color for people with vitiligo, a condition where the immune system attacks pigment-producing cells. Published in The Lancet, two trials involving 614 participants across 18 countries found that 23-25% of patients regained significant facial color, compared to 6-7% in placebo groups. While the drug offers a systemic alternative to topical creams and light therapy, it does not work for everyone, and long-term safety and efficacy remain under investigation.
Two large phase 3 trials demonstrate that upadacitinib, an arthritis medication, significantly improves hair regrowth in patients with severe alopecia areata. While the drug is already approved in the EU, it remains off-label in the US as AbbVie seeks FDA approval.
The Healthline piece surveys current and prospective hair‑loss treatments, highlighting established options finasteride and minoxidil as effective, affordable therapies, noting three FDA‑approved JAK inhibitors (Olumiant, Litfulo, Leqselvi) for alopecia areata with safety warnings, and surveying emerging approaches such as clascoterone, PP405, ET-02, stem-cell therapies, and fatty‑acid treatments. While these newer options show promise, many are still in early trials, and long‑term durability and safety remain uncertain. Experts emphasize early intervention and consulting ABHRS‑certified physicians for accurate diagnosis and personalized treatment planning.
New treatments, including FDA-approved JAK inhibitors like Leqselvi, are revolutionizing the management of alopecia areata, an autoimmune disease causing hair loss, offering hope for significant hair regrowth for many patients, though challenges such as side effects and accessibility remain.
A study warns that JAK inhibitors, common anti-inflammatory drugs used for conditions like rheumatoid arthritis and alopecia, may weaken the immune response to viruses, increasing the risk of severe infections, especially during outbreaks. Researchers suggest caution in prescribing these drugs and call for further research to optimize their use, particularly for vulnerable populations.
Researchers have successfully treated seven patients with toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) using JAK inhibitors, marking a potential cure for these rare and often fatal skin conditions. The treatment, which targets the JAK/STAT immune pathway, led to rapid recovery without side effects, offering hope for improved care in these life-threatening cases. The study, published in Nature, highlights the potential for clinical trials to further validate this breakthrough.
Science-backed methods to combat hair loss include platelet-rich plasma (PRP) injections to wake up dormant hair follicles, low-level laser therapy (LLLT) to stimulate hair growth, topical Minoxidil and oral Finasteride to treat pattern baldness, and JAK inhibitors to target alopecia areata, an autoimmune condition causing sudden hair loss. While a cure for baldness remains elusive, advancements in understanding and treating different forms of hair loss offer hope for those seeking to combat this common issue.
A new study confirms the effectiveness of newer oral medications called JAK inhibitors for rheumatoid arthritis (RA). The study found that most patients with RA who were treated with JAK inhibitors experienced symptom relief or even remission. The findings suggest that JAK inhibitors are effective in real-world settings, even for patients who have not responded well to standard treatments. While JAK inhibitors have been associated with some increased risks, such as heart attack and stroke, the overall risks appear to be low and similar to other RA medications. Long-term effectiveness and safety of JAK inhibitors still need further investigation.
Researchers at Emory University have been testing Jak inhibitors, specifically ruxolitinib, as a potential treatment to eliminate viral reservoirs of HIV in the body. In a study on individuals with a high reservoir viral load, the researchers found that ruxolitinib led to a significant decline in HIV hidden within DNA. The results suggest that Jak inhibitors could reverse immune dysfunction and decay the reservoir, potentially leading to a cure for HIV. Further research is needed to understand the impact on the entire viral reservoir in the body.
Researchers at Emory University have presented exciting findings in the pursuit of an HIV cure. The study demonstrated the potential of Jak inhibitors, specifically ruxolitinib, to significantly decay the viral reservoir in people with HIV, offering a novel pathway toward long-term remission or a cure. The results showed an estimated 99.99% clearance of the peripheral HIV-1 reservoir in less than three years. The study also highlighted the impact of ruxolitinib on immune activation, cell survival, and immune dysregulation. While further research and clinical trials are needed, these findings offer hope for the development of cure-based interventions for HIV.
An overactive inflammatory response might be the key to many long COVID cases. Around two-thirds of the 55 patients with long COVID showed persistently high levels of specific inflammation signals. The inflammation observed in patients with “inflammatory long COVID” mirrors that seen in autoimmune diseases like rheumatoid arthritis, suggesting that JAK inhibitors may be a potential treatment. Distinguishing between patients with inflammatory and non-inflammatory long COVID is critical for treatment as their conditions require different therapeutic approaches. Targeted anti-inflammatory treatments could potentially alleviate symptoms for this group.